CA2678630C - Synthesis of glyt-1 inhibitors - Google Patents
Synthesis of glyt-1 inhibitors Download PDFInfo
- Publication number
- CA2678630C CA2678630C CA2678630A CA2678630A CA2678630C CA 2678630 C CA2678630 C CA 2678630C CA 2678630 A CA2678630 A CA 2678630A CA 2678630 A CA2678630 A CA 2678630A CA 2678630 C CA2678630 C CA 2678630C
- Authority
- CA
- Canada
- Prior art keywords
- formula
- compound
- alkyl
- halogen
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07103485 | 2007-03-05 | ||
| EP07103485.4 | 2007-03-05 | ||
| PCT/EP2008/052244 WO2008107334A2 (en) | 2007-03-05 | 2008-02-25 | Process for the synthesis of glyt-1 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2678630A1 CA2678630A1 (en) | 2008-09-12 |
| CA2678630C true CA2678630C (en) | 2015-04-14 |
Family
ID=39469606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2678630A Active CA2678630C (en) | 2007-03-05 | 2008-02-25 | Synthesis of glyt-1 inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7812161B2 (enExample) |
| EP (1) | EP2131843B1 (enExample) |
| JP (1) | JP4745446B2 (enExample) |
| KR (1) | KR101143073B1 (enExample) |
| CN (1) | CN101622000B (enExample) |
| AT (1) | ATE532516T1 (enExample) |
| AU (1) | AU2008223915B2 (enExample) |
| BR (1) | BRPI0808570B8 (enExample) |
| CA (1) | CA2678630C (enExample) |
| ES (1) | ES2375585T3 (enExample) |
| IL (1) | IL200323A (enExample) |
| MX (1) | MX2009009065A (enExample) |
| WO (1) | WO2008107334A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5656474B2 (ja) | 2010-06-28 | 2015-01-21 | 関東化学株式会社 | 脂肪族光学活性フルオロアルコールの製造方法 |
| CN104628679B (zh) * | 2013-11-08 | 2018-02-09 | 江苏恩华药业股份有限公司 | Bitopertin的合成方法及其中间体 |
| CN106397312B (zh) * | 2015-07-31 | 2020-03-24 | 广东东阳光药业有限公司 | 一种制备glyt-1抑制剂的方法 |
| EP4087570A4 (en) | 2020-01-09 | 2024-04-03 | Disc Medicine, Inc. | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS |
| CN117567449A (zh) | 2020-10-13 | 2024-02-20 | 勃林格殷格翰国际有限公司 | 再加工方法 |
| WO2024042043A1 (en) | 2022-08-24 | 2024-02-29 | Boehringer Ingelheim International Gmbh | A scalable process for the preparation of a glyt-1 inhibitor |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3992441A (en) * | 1972-12-26 | 1976-11-16 | Pfizer Inc. | Sulfamylbenzoic acids |
| US4480102A (en) * | 1982-07-23 | 1984-10-30 | The Dow Chemical Company | 2,3-Difluoro-5-(trifluoromethyl)pyridine and methods of making and using the same |
| EP0370560B1 (en) * | 1988-11-24 | 1994-01-12 | Akzo Nobel N.V. | Pharmaceutical composition containing 1-[mono- or bis (trifluoromethyl)-2-pyridinyl] piperazines |
| DE4235155A1 (de) * | 1992-10-19 | 1994-04-21 | Basf Ag | Verfahren zur Herstellung von Methylsulfonylbenzoesäuren |
| WO1999054284A1 (en) * | 1998-04-20 | 1999-10-28 | Fujisawa Pharmaceutical Co., Ltd. | Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase |
| DE10112040A1 (de) | 2001-03-14 | 2002-10-02 | Aventis Pharma Gmbh | Verbessertes Verfahren zur Herstellung von Sulfonylcarboxamidderivaten |
| GB0227240D0 (en) * | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
| UA85194C2 (ru) * | 2003-08-11 | 2009-01-12 | Ф.Хоффманн-Ля Рош Аг | Пиперазины с or-замещенной фенильной группой и их применение как ингибиторов glyt 1 |
| RU2395502C2 (ru) * | 2004-12-09 | 2010-07-27 | Ф.Хоффманн-Ля Рош Аг | Производные фенил-пиперазин метанона |
| CA2593453A1 (en) * | 2005-01-06 | 2006-07-13 | F. Hoffmann-La Roche Ag | Sulfanyl substituted phenyl methanones as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders |
| AU2005324024B2 (en) * | 2005-01-07 | 2011-02-17 | F. Hoffmann-La Roche Ag | [4-(Heteroaryl) piperazin-1-yl]-(2,5-substituted -phenyl)methanone derivatives as glycine transporter 1 (GlyT-1) inhibitors for the treatment of neurological and neuropsychiatric disorders |
| WO2007006650A2 (en) * | 2005-07-08 | 2007-01-18 | F. Hoffmann-La Roche Ag | Asymmetric reduction of 1,1,1-trifluoroacetone |
-
2008
- 2008-02-25 WO PCT/EP2008/052244 patent/WO2008107334A2/en not_active Ceased
- 2008-02-25 KR KR1020097018418A patent/KR101143073B1/ko active Active
- 2008-02-25 EP EP08709206A patent/EP2131843B1/en active Active
- 2008-02-25 CN CN200880006900XA patent/CN101622000B/zh active Active
- 2008-02-25 AU AU2008223915A patent/AU2008223915B2/en active Active
- 2008-02-25 JP JP2009552166A patent/JP4745446B2/ja active Active
- 2008-02-25 CA CA2678630A patent/CA2678630C/en active Active
- 2008-02-25 MX MX2009009065A patent/MX2009009065A/es active IP Right Grant
- 2008-02-25 ES ES08709206T patent/ES2375585T3/es active Active
- 2008-02-25 AT AT08709206T patent/ATE532516T1/de active
- 2008-02-25 BR BRPI0808570A patent/BRPI0808570B8/pt active IP Right Grant
- 2008-02-27 US US12/038,006 patent/US7812161B2/en active Active
-
2009
- 2009-08-10 IL IL200323A patent/IL200323A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090110368A (ko) | 2009-10-21 |
| WO2008107334A3 (en) | 2008-10-23 |
| CA2678630A1 (en) | 2008-09-12 |
| EP2131843B1 (en) | 2011-11-09 |
| IL200323A0 (en) | 2010-04-29 |
| CN101622000A (zh) | 2010-01-06 |
| EP2131843A2 (en) | 2009-12-16 |
| BRPI0808570B8 (pt) | 2021-05-25 |
| JP2010520251A (ja) | 2010-06-10 |
| JP4745446B2 (ja) | 2011-08-10 |
| WO2008107334A2 (en) | 2008-09-12 |
| CN101622000B (zh) | 2012-07-04 |
| AU2008223915B2 (en) | 2013-05-02 |
| MX2009009065A (es) | 2009-08-31 |
| AU2008223915A1 (en) | 2008-09-12 |
| US20080221327A1 (en) | 2008-09-11 |
| ES2375585T3 (es) | 2012-03-02 |
| IL200323A (en) | 2013-11-28 |
| US7812161B2 (en) | 2010-10-12 |
| KR101143073B1 (ko) | 2012-05-08 |
| BRPI0808570A2 (pt) | 2014-09-02 |
| ATE532516T1 (de) | 2011-11-15 |
| BRPI0808570B1 (pt) | 2020-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2131843B1 (en) | Process for the synthesis of glyt-1 inhibitors | |
| CN111217819B (zh) | 乌帕替尼的合成方法 | |
| CN104387315B (zh) | 化合物i及（r）‑3‑氨基哌啶盐酸盐ii、其制备方法及其在利格列汀合成中的应用 | |
| CA2810393C (en) | Method of preparing 3-amino-4-(2-oxo-piperidin-1-yl)-butyric acid derivative for synthesizing medicament | |
| CN111592467A (zh) | 尼拉帕尼中间体及其制备方法和用途和尼拉帕尼的合成方法 | |
| Cole et al. | Reagent-free continuous thermal tert-butyl ester deprotection | |
| CA2645154C (en) | Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof | |
| US8471016B2 (en) | Process for the preparation of chiral beta amino carboxamide derivatives | |
| WO2021085468A1 (ja) | 高純度２－ナフチルアセトニトリル及びその製造方法 | |
| CN111233866B (zh) | 托法替尼或其盐的制备方法 | |
| WO2016124144A1 (zh) | 布瑞哌唑类似物的制备方法 | |
| CN115611858A (zh) | 一种全新的尼古丁及其衍生物的制备方法 | |
| WO2023226900A1 (zh) | 2-(哌嗪-2-基)乙腈类衍生物及其制备方法和应用 | |
| JP2010077089A (ja) | ハロピラジンカルボキサミド化合物の製造方法 | |
| CN108727224A (zh) | 药物合成用中间体的制备方法 | |
| CN104955820A (zh) | 4-(环丙基甲氧基)-n-(3,5-二氯-1-氧化-吡啶-4-基)-5-甲氧基吡啶-2-甲酰胺的制备方法 | |
| JP5397706B2 (ja) | 高純度１−ベンジル−３−アミノピロリジンの製造方法 | |
| JP2008115179A (ja) | 光学活性２−［（ｎ−ベンジルプロリル）アミノ］ベンゾフェノン化合物の製造方法 | |
| HK1113484B (en) | Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyoxy}-n-methylpyridine-2-carboxamide | |
| HK1162179A (en) | Process for the preparation of 2-(primary/secondary amino)hydrocarbyl)- carbamoyl-7-oxo-2,6-diaza-bicyclo[3.2.0.]heptane-6-sulfonic acid derivatives | |
| HK1113484A1 (en) | Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyoxy}-n-methylpyridine-2-carboxamide | |
| CA2875942A1 (en) | Preparation process of carboxylic acid derivatives and intermediates thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130116 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD Year of fee payment: 17 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250123 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250123 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250123 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD Year of fee payment: 18 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260121 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260121 |